

I. LGA (n= 210 (10.3%))			GDM		OR	aOR
			-	+		
		Total	148/1465 (10.1%)	62/575 (10.8%)	1.08 (CI 0.79-1.47)	1.02 (0.72-1.45)
Hypertension	-	188/1681 (11.2%)	133/1216 (10.9%)	55/465 (11.8%)	1.09 (CI 0.78-1.53)	1.11 (CI 0.77-1.60)
	+	21/358 (5.9%)	15/249 (6.0%)	6/109 (5.5%)	0.91 (CI 0.34-2.41)	0.40 (CI 0.11-1.41)
OR		0.50 (CI 0.31-0.79)	0.52 (CI 0.30-0.91)	0.43 (CI 0.18-1.04)		
aOR		0.46 (CI 0.28-0.77)	0.54 (CI 0.31-0.97)	0.30 (CI 0.11-0.87)		
Obesity	-	139/1415 (9.8%)	106/1103 (9.6%)	33/312 (10.6%)	1.11 (CI 0.74-1.68)	1.21 (CI 0.78-1.89)
	+	71/618 (11.5%)	42/358 (11.7%)	29/260 (11.2%)	0.95 (CI 0.57-1.56)	0.75 (CI 0.43-1.33)
OR		1.19 (CI 0.88-1.61)	1.25 (CI 0.86-1.83)	1.06 (CI 0.63-1.80)		
aOR		1.17 (CI 0.84-1.63)	1.25 (CI 0.83-1.88)	1.05 (CI 0.58-1.92)		
Dyslipidemia	-	195/1922 (10.1%)	139/1397 (9.9%)	56/525 (10.7%)	1.08 (CI 0.78-1.50)	1.08 (CI 0.75-1.55)
	+	15/117 (12.8%)	9/67 (13.4%)	6/50 (12.0%)	0.88 (CI 0.29-2.65)	0.41 (CI 0.09-1.87)
OR		1.30 (CI 0.74-2.28)	1.40 (CI 0.68-2.90)	1.14 (CI 0.47-2.80)		
aOR		1.15 (CI 0.61-2.16)	1.44 (CI 0.69-3.01)	0.70 (CI 0.20-2.41)		
Proteinuria	-	205/1967 (10.4%)	144/1419 (10.1%)	61/548 (11.1%)	1.11 (CI 0.81-1.52)	1.02 (CI 0.72-1.45)
	+	1/26 (3.8%)	0/15 (0.0%)	1/11 (9.1%)	NA	NA
OR		0.34 (CI 0.05-2.55)	NA	0.80 (CI 0.10-6.35)		
aOR		NA	NA	NA		
≥ 2 constituents	-	187/1793 (10.4%)	135/1326 (10.2%)	52/467 (11.1%)	1.11 (CI 0.79-1.55)	-
	+	18/191 (9.4%)	9/103 (8.7%)	9/88 (10.2%)	1.19 (CI 0.45-3.14)	-
OR		0.89 (CI 0.54-1.49)	0.85 (CI 0.42-1.71)	0.91 (CI 0.43-1.92)		
II. SGA (n=200 (9.8%))		Total	153/1465 (10.4%)	47/575(8.2%)	0.76 (CI 0.54-1.08)	0.78 (CI 0.54-1.12)
Hypertension	-	153/1681 (9.1%)	118/1216 (9.7%)	35/465 (7.5%)	0.76 (CI 0.51-1.12)	0.73 (CI 0.48-1.11)
	+	47/358 (13.1%)	35/249 (14.1%)	12/109 (11.0%)	0.76 (CI 0.38-1.52)	1.02 (CI 0.47-2.22)
OR		1.51 (CI 1.07-2.14)	1.52 (CI 1.02-2.28)	1.52 (CI 0.76-3.04)		
aOR		1.59 (CI 1.09-2.31)	1.54 (CI 1.00-2.39)	1.78 (CI 0.82-3.88)		
Obesity	-	149/1415 (10.5%)	116/1103 (10.5%)	33/312 (10.6%)	1.01 (CI 0.67-1.52)	1.00 (CI 0.65-1.54)
	+	51/618 (8.3%)	37/358 (10.3%)	14/260 (5.4%)	0.49 (CI 0.26-0.93)	0.48 (CI 0.25-0.94)
OR		0.76 (CI 0.55-1.07)	0.98 (CI 0.66-1.45)	0.48 (CI 0.25-0.92)		
aOR		0.81 (CI 0.57-1.15)	1.06 (CI 0.70-1.59)	0.52 (CI 0.26-1.07)		
Dyslipidemia	-	192/1922 (10.0%)	149/1397 (10.7%)	43/525 (8.2%)	0.75 (CI 0.52-1.07)	0.74 (CI 0.51-1.08)
	+	8/117 (6.8%)	4/67 (6.0%)	4/50 (8.0%)	1.37 (CI 0.33-5.76)	2.55 (CI 0.51-12.80)
OR		0.66 (CI 0.32-1.38)	0.53 (CI 0.19-1.48)	0.98 (CI 0.34-2.84)		
aOR		0.71 (CI 0.34-1.50)	0.58 (CI 0.21-1.63)	0.95 (CI 0.30-2.99)		
Proteinuria	-	191/1967 (9.7%)	150/1419 (10.6%)	41/548 (7.5%)	0.68 (CI 0.48-0.98)	0.72 (CI 0.49-1.04)
	+	6/26 (23.1%)	2/15 (13.3%)	4/11 (36.4%)	3.71 (CI 0.54-25.59)	NA
OR		2.79 (CI 1.11-7.03)	1.30 (CI 0.29-5.82)	7.07 (CI 1.99-25.14)		
aOR		1.84 (CI 0.60-5.70)	NA	9.96 (CI 1.98-50.01)		
≥ 2 constituents	-	178/1793 (9.9%)	140/1326 (10.6%)	38/467 (8.1%)	0.75 (CI 0.52-1.09)	-
	+	19/191 (9.9%)	12/103 (11.7%)	7/88 (8.0%)	0.65 (CI 0.25-1.74)	-
OR		1.00 (CI 0.61-1.65)	1.12 (CI 0.60-2.09)	0.98 (CI 0.42-2.26)		

Table S1. Odds ratios for LGA and SGA. In vertical direction, ORs are calculated to explore the effect of the constituents for the group as a whole and sub-grouped without and with GDM. Along the horizontal axis, ORs are also detailed to explore an effect of GDM. Adjustments were made for the other constituents of the metabolic syndrome, age, Northern European ethnicity and gestational age at time of OGTT.